Principal Accounting Officer Barton Shane exercised 59,934 shares at a strike of $6.58 and sold $1,576,752 worth of shares (62,566 units at $25.20) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)
$BIOA
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | |||||||||||||||||
| Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | ||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Issuer Name and Ticker or Trading Symbol
BioAge Labs, Inc. [ BIOA ] | 5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| |||||||||||||||||||||||||
| 2a. Foreign Trading Symbol
| |||||||||||||||||||||||||||
| 3. Date of Earliest Transaction
(Month/Day/Year) 06/29/2026 | 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||||||||||||
| 4. If Amendment, Date of Original Filed
(Month/Day/Year) |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
| Code | V | Amount | (A) or (D) | Price | ||||||
| Common Stock | 06/29/2026 | M(1) | 9,301 | A | $10.85 | 11,933 | D | |||
| Common Stock | 06/29/2026 | M(1) | 7,261 | A | $8.39 | 19,194 | D | |||
| Common Stock | 06/29/2026 | M(1) | 8,958 | A | $4.3 | 28,152 | D | |||
| Common Stock | 06/29/2026 | M(1) | 14,198 | A | $4.38 | 42,350 | D | |||
| Common Stock | 06/29/2026 | S(1) | 42,350 | D | $25.2084(2) | 0 | D | |||
| Common Stock | 06/30/2026 | M(1) | 4,290 | A | $10.85 | 4,290 | D | |||
| Common Stock | 06/30/2026 | M(1) | 4,000 | A | $8.39 | 8,290 | D | |||
| Common Stock | 06/30/2026 | M(1) | 4,065 | A | $4.3 | 12,355 | D | |||
| Common Stock | 06/30/2026 | M(1) | 7,861 | A | $4.38 | 20,216 | D | |||
| Common Stock | 06/30/2026 | S(1) | 20,216 | D | $25.1868(3) | 0 | D | |||
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Stock Option (Right to Buy) | $10.85 | 06/29/2026 | M(1) | 9,301 | (4) | 09/26/2033 | Common Stock | 9,301 | $0 | 17,589 | D | ||||
| Stock Option (Right to Buy) | $8.39 | 06/29/2026 | M(1) | 7,261 | (5) | 04/16/2034 | Common Stock | 7,261 | $0 | 21,016 | D | ||||
| Stock Option (Right to Buy) | $4.3 | 06/29/2026 | M(1) | 8,958 | (6) | 12/17/2034 | Common Stock | 8,958 | $0 | 31,042 | D | ||||
| Stock Option (Right to Buy) | $4.38 | 06/29/2026 | M(1) | 14,198 | (7) | 02/17/2035 | Common Stock | 14,198 | $0 | 75,802 | D | ||||
| Stock Option (Right to Buy) | $10.85 | 06/30/2026 | M(1) | 4,290 | (4) | 09/26/2033 | Common Stock | 4,290 | $0 | 13,299 | D | ||||
| Stock Option (Right to Buy) | $8.39 | 06/30/2026 | M(1) | 4,000 | (5) | 04/16/2034 | Common Stock | 4,000 | $0 | 17,016 | D | ||||
| Stock Option (Right to Buy) | $4.3 | 06/30/2026 | M(1) | 4,065 | (6) | 12/17/2034 | Common Stock | 4,065 | $0 | 26,977 | D | ||||
| Stock Option (Right to Buy) | $4.38 | 06/30/2026 | M(1) | 7,861 | (7) | 02/17/2035 | Common Stock | 7,861 | $0 | 67,941 | D | ||||
| Explanation of Responses: |
| 1. The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025. |
| 2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.79 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. |
| 3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.42 per share, inclusive. |
| 4. The option vested as to 1/4th of the total award on September 25, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| 5. The option vested as to 1/4th of the total award on October 17, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| 6. The option vested as to 1/4th of the total award on October 26, 2024, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| 7. The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on February 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| /s/ Dov A. Goldstein as attorney-in-fact | 07/01/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 4: SEC 1474 (03-26) | ||